Press Releases SOCL CAPI

Equities

DNAC

KYG8253W1096

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
2.81 ^USD	+7.66%		+27.73%	-71.44%

2022	Social Capital Suvretta Holdings Corp. III Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
2022	ProKidney Completes SPAC Merger With Social Capital Suvretta Holdings; Shares to Start Nasdaq Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SOCL CAPI : Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III - Form 8-K	15/07/22	PU
Social Capital Suvretta III : Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III - Form 8-K	12/07/22	PU
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III	12/07/22	AQ
Social Capital Suvretta III : Announces Reconvened Extraordinary General Meeting of Shareholders - Form 8-K	11/07/22	PU
SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	11/07/22	AQ
Social Capital Suvretta Holdings Corp. III Announces Reconvened Extraordinary General Meeting of Shareholders	09/07/22	BU
SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III : Other Events (form 8-K)	06/07/22	AQ
Social Capital Suvretta III : REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Form 8-K/A	10/06/22	PU
SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III Other Events, Financial Statements and Exhibits (form 8-K/A)	10/06/22	AQ
Observed Safety Profile Supports Bilateral Dosing of ProKidney’s REACT™ – 007 Update	07/06/22	AQ
ProKidney to present at upcoming investor conferences	20/05/22	AQ
SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	16/05/22	AQ
SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	28/04/22	AQ
SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	22/04/22	AQ
ProKidney and Social Capital Suvretta Holdings Corp. III (“SCS”) to Host Analyst and Investor Day on April 28, 2022	18/04/22	AQ
ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT®	12/04/22	AQ
SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	24/03/22	AQ
ProKidney Announces Online Publication of Trial Design for Phase II Multicenter Clinical Trial of REACT® Autologous Cell Therapy for Treatment of Chronic Kidney Disease	27/01/22	AQ
SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K/A)	21/01/22	AQ
SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	18/01/22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases SOCL CAPI

Equities

DNAC

KYG8253W1096

Press Releases

Filters